Notably, GSK126 (one of the EZH2 inhibitors) treatment in the KRAS-mutant NSCLC cell H358 and A549 resulted in an increase in phosphorylated AKT and ERK, potentially promoting cell proliferation190–192. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.